Glenmark Names Priyanka Tewari Head of Marketing: Why It Matters

Pharmaceutical marketing rarely makes headlines outside trade press. It should. It is one of the few categories where the person who chooses the brand is not the person who pays for it, does not consume it, and is legally restricted from being advertised to in most conventional ways. That makes it a fascinating laboratory for persuasion.

So a leadership move in the space is worth a closer look. According to HR Today, Priyanka Tewari has joined Glenmark Pharmaceuticals as Head of Marketing, stepping into the company’s marketing leadership team with nearly 18 years across pharmaceutical marketing, brand management and product strategy.

The career ladder behind the appointment

Tewari joins from Alkem Laboratories, where she moved through three marketing roles in under four years — joining as Assistant Marketing Manager in December 2022, becoming Marketing Manager in April 2024 and Senior Marketing Manager in April 2026. At Alkem she worked on CLAVAM, one of the better-known brands in the Indian pharmaceutical market.

Before that she was Group Product Manager at Zydus Group, handling the Ampilox brand, and held the same designation at Hetero Healthcare on the Opox brand. Earlier stints include more than four years at Ipca Laboratories as Senior Product Manager on brands including Vinicor and Rxplus, a Brand Manager role at Panacea Biotec, and international marketing and product management responsibilities at Unichem Laboratories and Plethico Pharmaceuticals. She began in 2008 as a Product Executive at Ajanta Pharma and holds an MBA in Marketing from NMIMS CDOE.

Glenmark itself is a research-led global pharmaceutical company spanning branded generics, specialty and over-the-counter products, operating in more than 80 countries with ten manufacturing facilities across four continents, and a presence in dermatology, respiratory and oncology.

Why branded generics are a masterclass in positioning

Here is the puzzle that makes this beat interesting to anyone who studies buying behaviour: in a branded generic, the molecule is identical across a dozen competitors. The active ingredient does not vary. The price often barely varies. And yet market share varies enormously.

What is being sold, then, is not chemistry. It is reduction of perceived risk. A prescriber’s decision is a high-stakes, low-differentiation choice made under time pressure — exactly the conditions in which humans reach for heuristics rather than analysis.

The heuristics that do the heavy lifting in this category are familiar to any brand marketer:

• Availability — the brand name that surfaces fastest in memory wins the script. Repetition, not novelty, is the job.
• Authority transfer — endorsement by respected clinicians, journals and institutions substitutes for product proof.
• Consistency bias — once a doctor has prescribed a brand successfully, switching carries psychological cost far beyond the rupee difference.
• Name fluency — easier-to-pronounce brand names get recalled and written more often. CLAVAM, Ampilox, Opox are short, hard-consonant, fast to say and fast to write.
• Trust as the product — in health, the buyer is purchasing certainty about downside, not upside.

The India context: two audiences, one brand

Indian pharma marketing is increasingly a dual-audience game. The prescriber remains the gatekeeper, but the patient now Googles the molecule, compares strips at the chemist, and has opinions. That means brand teams have to build professional credibility and consumer familiarity simultaneously — without letting the two tones contradict each other.

Leaders who have run both domestic and international brand portfolios, as Tewari has, tend to be hired precisely for that reconciliation problem: how do you keep a scientific proposition rigorous enough for a specialist and legible enough for a worried parent at a pharmacy counter?

What marketers outside pharma can borrow

Three transferable lessons, whatever you sell:

1. When the product is identical, the brand is the differentiator — and trust is the brand. Commoditised categories are not brand-proof; they are brand-dependent.

2. Design for recall, not for applause. Pharma brand names are engineered for speed of retrieval. Most consumer brand names are engineered for the founder’s ego.

3. Sell the avoidance of loss. In categories where the downside is scary, framing around risk reduction beats framing around benefit gain almost every time.

Tewari’s move is, on paper, one line in an appointments column. Read properly, it is a reminder that some of the sharpest positioning work in India happens where nobody is allowed to run an ad.

Source: HR TODAY